Literature DB >> 9988225

Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis.

N O Schmidt1, M Westphal, C Hagel, S Ergün, D Stavrou, E M Rosen, K Lamszus.   

Abstract

Angiogenesis is a possible target in the treatment of human gliomas. To evaluate the role of 3 growth factors, vascular endothelial growth factor (VEGF), hepatocyte growth factor/scatter factor (HGF/SF) and basic fibroblast growth factor (bFGF), in the angiogenic cascade, we determined their levels in extracts of 71 gliomas by enzyme-linked immunosorbent assay (ELISA). The levels of bFGF were only marginally different between gliomas of World Health Organization (WHO) grade II (low grade) and grades III and IV (high grade). In contrast, the mean concentrations of VEGF were 11-fold higher in high-grade tumors and those of HGF/SF 7-fold, respectively. Both were highly significantly correlated with microvessel density (p < 0.001) as determined by immunostaining for factor VIII-related antigen. In addition, VEGF and HGF/SF appeared to be independent predictive parameters for glioma microvessel density as determined by multiple regression analysis. We measured the capacity of all 3 factors to induce endothelial tube formation in a collagen gel. In this assay, bFGF was found to be an essential cofactor with which VEGF as well as HGF/SF were able to synergize independently. According to the concentrations of angiogenic factors, extracts from high-grade tumors were significantly more potent in the tube formation assay than the low-grade extracts (p = 0.02). Adding neutralizing antibodies to bFGF, VEGF and HGF/SF together with the extracts, tube formation was inhibited by up to 98%, 62% and 54%, respectively. Our findings suggest that bFGF is an essential cofactor for angiogenesis in gliomas, but in itself is insufficient as it is present already in the sparsely vascularized low-grade tumors. Upon induction of angiogenesis in high-grade tumors, bFGF may synergize with rising levels of not only VEGF but possibly also with HGF/SF, which appears here to be an independent angiogenic factor.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9988225     DOI: 10.1002/(sici)1097-0215(19990219)84:1<10::aid-ijc3>3.0.co;2-l

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  78 in total

1.  Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.

Authors:  Tracy T Batchelor; Dan G Duda; Emmanuelle di Tomaso; Marek Ancukiewicz; Scott R Plotkin; Elizabeth Gerstner; April F Eichler; Jan Drappatz; Fred H Hochberg; Thomas Benner; David N Louis; Kenneth S Cohen; Houng Chea; Alexis Exarhopoulos; Jay S Loeffler; Marsha A Moses; Percy Ivy; A Gregory Sorensen; Patrick Y Wen; Rakesh K Jain
Journal:  J Clin Oncol       Date:  2010-05-10       Impact factor: 44.544

Review 2.  Antiangiogenic therapies for glioblastoma.

Authors:  Isabel Arrillaga-Romany; Andrew D Norden
Journal:  CNS Oncol       Date:  2014

Review 3.  New Directions in Anti-Angiogenic Therapy for Glioblastoma.

Authors:  Nancy Wang; Rakesh K Jain; Tracy T Batchelor
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

Review 4.  Antiangiogenic strategies for treatment of malignant gliomas.

Authors:  Andrew S Chi; Andrew D Norden; Patrick Y Wen
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

5.  Histopathological vascular investigation of the peritumoral brain zone of glioblastomas.

Authors:  Ryota Tamura; Kentaro Ohara; Hikaru Sasaki; Yukina Morimoto; Kazunari Yoshida; Masahiro Toda
Journal:  J Neurooncol       Date:  2017-11-29       Impact factor: 4.130

6.  The clinical value of serum hepatocyte growth factor levels in patients undergoing primary radiotherapy for glioma: effect on progression-free survival.

Authors:  Qing-le Liang; Zheng-ying Mo; Ping Wang; Xiao Li; Zhi-xiang Liu; Zhang-ming Zhou
Journal:  Med Oncol       Date:  2014-07-27       Impact factor: 3.064

7.  Combined effects of radiotherapy and angiostatin gene therapy in glioma tumor model.

Authors:  F Griscelli; H Li; C Cheong; P Opolon; A Bennaceur-Griscelli; G Vassal; J Soria; C Soria; H Lu; M Perricaudet; P Yeh
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

8.  CT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy.

Authors:  J Dawn Waters; Carlos Sanchez; Ayguen Sahin; Diahnn Futalan; David D Gonda; Justin K Scheer; Johnny Akers; Kamalakannan Palanichamy; Peter Waterman; Arnab Chakravarti; Ralph Weissleder; Brent Morse; Nick Marsh; Eric Furfine; Clark C Chen; Irvith Carvajal; Bob S Carter
Journal:  J Neurooncol       Date:  2012-08-09       Impact factor: 4.130

9.  Phenotypic Screening of Chemical Libraries Enriched by Molecular Docking to Multiple Targets Selected from Glioblastoma Genomic Data.

Authors:  David Xu; Donghui Zhou; Khuchtumur Bum-Erdene; Barbara J Bailey; Kamakshi Sishtla; Sheng Liu; Jun Wan; Uma K Aryal; Jonathan A Lee; Clark D Wells; Melissa L Fishel; Timothy W Corson; Karen E Pollok; Samy O Meroueh
Journal:  ACS Chem Biol       Date:  2020-05-21       Impact factor: 5.100

10.  Usefulness of ¹¹C-methionine positron emission tomography for treatment-decision making in cases of non-enhancing glioma-like brain lesions.

Authors:  Atsushi Watanabe; Yoshihiro Muragaki; Takashi Maruyama; Jun Shinoda; Yoshikazu Okada
Journal:  J Neurooncol       Date:  2015-11-26       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.